Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age
NCT ID: NCT05193279
Last Updated: 2023-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2/PHASE3
INTERVENTIONAL
2022-10-05
2022-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COVAXIN in a Pediatric Cohort
NCT04918797
Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years
NCT05468736
A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine
NCT05239975
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
NCT05436834
Safety of Pediatric COVID-19 Vaccination
NCT05157191
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SCB-2019/SCB-2019/placebo, 12 to < 18 yrs
Day 1 and 22: SCB-2019, Day 43: placebo
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Placebo/SCB-2019/SCB-2019, 12 to < 18 years
Day 1: placebo, Day 22 and 43: SCB-2019
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
SCB-2019/placebo/SCB-2019, 12 to < 18 years
Day 1 and 43: SCB-2019, Day 22: placebo
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Low dose SCB-2019, 5 to < 12 years
Day 1 and 22: SCB-2019
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Mid dose SCB-2019, 5 to < 12 years
Day 1 and 22: SCB-2019
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
High dose SCB-2019, 5 to < 12 years
Day 1 and 22: SCB-2019
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
SCB-2019/SCB-2019/placebo, 5 to < 12 yrs
Day 1 and 22: SCB-2019, Day 43: placebo
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Placebo/SCB-2019/SCB-2019, 5 to < 12 years
Day 1: placebo, Day 22 and 43: SCB-2019
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
SCB-2019/placebo/SCB-2019, 5 to < 12 years
Day 1 and 43: SCB-2019, Day 22: placebo
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Low dose SCB-2019, 2 to < 5 years
Day 1 and 22: SCB-2019
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Mid dose SCB-2019, 2 to < 5 years
Day 1 and 22: SCB-2019
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
High dose SCB-2019, 2 to < 5 years
Day 1 and 22: SCB-2019
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
SCB-2019/SCB-2019/placebo, 2 to < 5 yrs
Day 1 and 22: SCB-2019, Day 43: placebo
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Placebo/SCB-2019/SCB-2019, 2 to < 5 years
Day 1: placebo, Day 22 and 43: SCB-2019
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
SCB-2019/placebo/SCB-2019, 2 to < 5 years
Day 1 and 43: SCB-2019, Day 22: placebo
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Low dose SCB-2019, birth to < 2 years
Day 1 and 22: SCB-2019
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Mid dose SCB-2019, birth to < 2 years
Day 1 and 22: SCB-2019
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
High dose SCB-2019, birth to < 2 years
Day 1 and 22: SCB-2019
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
SCB-2019/SCB-2019/placebo, birth to < 2 yrs
Day 1 and 22: SCB-2019, Day 43: placebo
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Placebo/SCB-2019/SCB-2019, birth to < 2 years
Day 1: placebo, Day 22 and 43: SCB-2019
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
SCB-2019/placebo/SCB-2019, birth to < 2 years
Day 1 and 43: SCB-2019, Day 22: placebo
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals and their legally authorized representative (LAR) are willing and able to comply with study requirements, including all scheduled visits, vaccinations, laboratory tests and other study procedures.
* Individuals are willing and able to give an assent (if applicable) and their LARs are willing and able to give informed consent on their behalf, prior to screening
* Healthy participants (phase 2 and phase 3) or participants with pre-existing medical conditions who are in a stable medical condition (phase 2)
* For infants (\<1-year-old) - born at full term (gestational age ≥37 weeks) and with a normal birth weight (≥2500 grams).
* Female participants of childbearing potential may be enrolled in the study, if the participant has practiced highly effective contraception for 30 days prior to vaccination, and has a negative pregnancy test on the day of vaccination and has agreed to continue adequate contraception for 3 months after the last vaccination
Exclusion Criteria
* Individuals with laboratory-confirmed SARS-CoV-2 infection \[as defined by Rapid COVID Antigen Test or an equivalent at Day 1\] or with history of laboratory-confirmed/medically-diagnosed COVID-19 (for phase 2 participants only).
* Individuals who have received an investigational or licensed COVID-19 vaccine prior to Day 1, or plan to receive an investigational or licensed COVID-19 vaccine during the study period.
* Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease \[e.g., malignancy, human immunodeficiency virus (HIV) infection\] or immunosuppressive/cytotoxic therapy (e.g., systemic corticosteroids, medications used for cancer chemotherapy, organ transplantation or to treat autoimmune disorders) within 3 months prior to Day 1. Inhaled, intranasal, topical steroids as well as a single dose of systemic steroids, are allowed.
* Individuals with any progressive or severe neurologic disorder, seizure disorder (including febrile seizures) or history of Guillain-Barré syndrome.
* Individuals who are pregnant, or breastfeeding, or planning to become pregnant while enrolled in this study or during the study period.
* Individuals who have a history of severe adverse reaction associated with a vaccine or severe allergic reaction
* Individuals who have received any other investigational product within 30 days prior to Day 1 or intend to participate in another clinical study at any time during the conduct of this study.
* Individuals who have received any other licensed vaccines within 14 days prior to enrollment in this study or who are planning to receive any vaccine up to 28 days after the second (phase 2) or third (phase 3) vaccination.
* Individuals with known bleeding disorder that would, in the opinion of the investigator, contraindicate intramuscular injection
* Administration of intravenous immunoglobulins and/or any blood products within 3 months prior to enrollment or planned administration during the study period
* Individuals with any condition that, in the opinion of the investigator, would interfere with the primary study objectives or pose additional risk to the participant
17 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clover Biopharmaceuticals AUS Pty
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clínica de la Costa Ltda
Barranquilla, , Colombia
Centro de Estudios en Infectología Pediátrica S.A.S. - CEIP S.A.S.
Cali, , Colombia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLO-SCB-2019-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.